FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. The only peptide with full regulatory approval for a sexual health indication. Works through melanocortin-4 receptor activation in the brain to increase desire rather than just physical arousal.
Key Research Benefits
Best For
Low sexual desire and HSDD research
Considerations
Can cause nausea, flushing, and transient blood pressure changes. Limited to 8 doses per month in approved labeling.